SCHEDULE: Commodore Capital Discloses 9.9% Stake in Immunic

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in Immunic, Inc., primarily through warrants.

Summary

• Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, has disclosed a 9.9% beneficial ownership stake in Immunic, Inc.
• The aggregate amount beneficially owned by the reporting persons is 13,350,121 shares of Common Stock.
• This ownership includes 11,454,000 shares acquirable through Pre-Funded Warrants and 1,896,121 shares acquirable through Common Warrants.
• The warrants are subject to a beneficial ownership limitation of 9.99%.
• An additional 9,557,879 shares underlying Common Warrants are excluded from the reported beneficial ownership due to this limitation.
• The ownership percentage is calculated based on 120,284,724 common shares outstanding as of November 11, 2025, plus the shares acquirable through the warrants.
• The securities were not acquired for the purpose of changing or influencing control of Immunic, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A significant stake by an institutional investor like Commodore Capital can signal confidence in Immunic, Inc., although the passive nature of the filing (no intent to influence control) limits the immediate upside from potential activism.

Positives

• A significant institutional investor, Commodore Capital, has taken a substantial 9.9% stake in Immunic, Inc., potentially signaling confidence in the company's long-term prospects.
• The investment is structured through warrants, indicating a strategic entry point and potential for future capital deployment upon exercise.

Negatives

• The beneficial ownership limitation of 9.99% on the warrants suggests a cap on the immediate voting power and influence of Commodore Capital, potentially limiting their ability to drive significant corporate changes in the short term.

Risks

• The value of the investment is tied to the performance of Immunic, Inc.'s common stock, which carries inherent market and operational risks.
• The exercise of warrants could lead to dilution for existing shareholders if not managed effectively by the company.

Future Outlook

The filing does not provide a future outlook for Immunic, Inc. from the issuer's perspective. It primarily discloses the current beneficial ownership stake of Commodore Capital and its affiliates.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by an investment firm like Commodore Capital in a biotechnology company such as Immunic, Inc. can be interpreted by the market as a vote of confidence. In the biotech sector, where R&D and clinical trial success are critical, institutional backing can provide stability and potentially attract further investment, distinguishing it from smaller, less-backed ventures.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.9% stake is a substantial position for an institutional investor, often approaching the threshold where more active engagement or board representation might be considered, although the filing explicitly states no intent to influence control.
• For comparison, similar significant stakes by activist or strategic investors in other biotech firms (e.g., a 5-10% stake by firms like Baker Bros. Advisors in companies like Incyte or Seagen) often precede increased scrutiny or strategic shifts, even if not explicitly stated as the purpose of the investment.
• The 9.99% beneficial ownership limitation is a common mechanism used by investors to avoid triggering certain regulatory requirements or to maintain flexibility.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence and potentially attract other investors, but the exercise of warrants could lead to dilution.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, even if the investor states no intent to influence control.

Next Steps

• Commodore Capital LP and its affiliates will continue to monitor their investment in Immunic, Inc.
• Future amendments to this Schedule 13G will be filed on behalf of all undersigned reporting persons.

Key Dates

Recommendation

A significant stake by an institutional investor like Commodore Capital is generally a positive signal, suggesting confidence in Immunic, Inc.'s long-term value. However, the filing is a passive disclosure of ownership and explicitly states no intent to influence control, limiting immediate catalysts for a 'buy' recommendation. The existence of warrants, while a future potential for capital, also introduces potential dilution. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor Immunic's operational performance and Commodore Capital's future actions.

Keywords

Immunic Inc, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Pre-Funded Warrants, Investment Management, Biotechnology, Pharmaceuticals